JP2013518923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518923A5 JP2013518923A5 JP2012552469A JP2012552469A JP2013518923A5 JP 2013518923 A5 JP2013518923 A5 JP 2013518923A5 JP 2012552469 A JP2012552469 A JP 2012552469A JP 2012552469 A JP2012552469 A JP 2012552469A JP 2013518923 A5 JP2013518923 A5 JP 2013518923A5
- Authority
- JP
- Japan
- Prior art keywords
- single bond
- represented
- bond
- following structure
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- -1 4-biphenylyl Chemical group 0.000 claims 5
- 229930194542 Keto Natural products 0.000 claims 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000000468 ketone group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 2
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930185087 sanglifehrin Natural products 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- FEOLNMRUZBLTJM-UGFGJWANSA-N CC(C)[C@@H](C(NC(C)(Cc1cc(O)ccc1)C(N(CCC1)NC1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@@H](C)[C@H]1CCC(C)=O)O)/C(/C)=C/C=C/C(N2OCCCC2)=O)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(NC(C)(Cc1cc(O)ccc1)C(N(CCC1)NC1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@@H](C)[C@H]1CCC(C)=O)O)/C(/C)=C/C=C/C(N2OCCCC2)=O)=O)=O)=O)NC1=O FEOLNMRUZBLTJM-UGFGJWANSA-N 0.000 description 1
- 0 CC(C)[C@@](C(NC(C1)([C@@]1c1cc(O)ccc1)C(N(CCCC1C(O[C@@](CC=CC=C[C@@]([C@](C)[C@]([C@]2CCC(C)=O)O*)O)C(C)=CC=CC(*)=O)=O)C1C=N)=O)=O)NC2=O Chemical compound CC(C)[C@@](C(NC(C1)([C@@]1c1cc(O)ccc1)C(N(CCCC1C(O[C@@](CC=CC=C[C@@]([C@](C)[C@]([C@]2CCC(C)=O)O*)O)C(C)=CC=CC(*)=O)=O)C1C=N)=O)=O)NC2=O 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000134 cyclophilin inhibitor Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1002097.2 | 2010-02-09 | ||
| GBGB1002097.2A GB201002097D0 (en) | 2010-02-09 | 2010-02-09 | Novel compounds |
| GB1006128.1 | 2010-04-13 | ||
| GBGB1006128.1A GB201006128D0 (en) | 2010-04-13 | 2010-04-13 | Novel compounds |
| GB1101085.7 | 2011-01-21 | ||
| GBGB1101085.7A GB201101085D0 (en) | 2011-01-21 | 2011-01-21 | Novel compounds |
| PCT/GB2011/050236 WO2011098809A1 (en) | 2010-02-09 | 2011-02-09 | Sanglifehrin based compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518923A JP2013518923A (ja) | 2013-05-23 |
| JP2013518923A5 true JP2013518923A5 (enExample) | 2015-11-19 |
| JP5894935B2 JP5894935B2 (ja) | 2016-03-30 |
Family
ID=43836693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552469A Expired - Fee Related JP5894935B2 (ja) | 2010-02-09 | 2011-02-09 | サングリフェリン系化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9119853B2 (enExample) |
| EP (1) | EP2533784B1 (enExample) |
| JP (1) | JP5894935B2 (enExample) |
| AU (1) | AU2011214135B2 (enExample) |
| BR (1) | BR112012019866A8 (enExample) |
| CA (1) | CA2788761C (enExample) |
| ES (1) | ES2541853T3 (enExample) |
| MX (1) | MX2012008873A (enExample) |
| WO (1) | WO2011098809A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201008123D0 (en) * | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| GB201118334D0 (en) * | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
| EP3541388A1 (en) | 2016-11-18 | 2019-09-25 | Neurovive Pharmaceutical AB | Use of sanglifehrin macrocyclic analogues as anticancer compounds |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| SK182498A3 (en) | 1996-07-05 | 2000-05-16 | Biotica Tech Ltd | Erythromycins and process for their preparation |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| EP1893211B1 (en) | 2005-06-17 | 2011-09-14 | Novartis AG | Use of sanglifehrin in hcv |
| MX2009007045A (es) | 2007-01-04 | 2009-10-07 | Debiopharm Sa | Ciclosporina no inmunosupresora para el tratamiento de distrofia muscular congenita de ullrich. |
| EP2342335B1 (en) | 2008-09-24 | 2015-09-16 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Novel gene cluster |
| JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2011
- 2011-02-09 JP JP2012552469A patent/JP5894935B2/ja not_active Expired - Fee Related
- 2011-02-09 US US13/575,212 patent/US9119853B2/en active Active
- 2011-02-09 BR BR112012019866A patent/BR112012019866A8/pt not_active Application Discontinuation
- 2011-02-09 CA CA2788761A patent/CA2788761C/en not_active Expired - Fee Related
- 2011-02-09 WO PCT/GB2011/050236 patent/WO2011098809A1/en not_active Ceased
- 2011-02-09 EP EP20110704308 patent/EP2533784B1/en not_active Not-in-force
- 2011-02-09 AU AU2011214135A patent/AU2011214135B2/en not_active Ceased
- 2011-02-09 MX MX2012008873A patent/MX2012008873A/es active IP Right Grant
- 2011-02-09 ES ES11704308.3T patent/ES2541853T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518923A5 (enExample) | ||
| EP2176248B1 (en) | New antimicrobial compounds, their synthesis and their use for treatment of mammalian infections | |
| RU2664534C9 (ru) | Пролекарственная форма тенофовира и ее фармацевтические применения | |
| US20110160193A1 (en) | New Benzothiazinone Derivatives and Their Use as Antibacterial Agents | |
| KR101851774B1 (ko) | 2-피페라진-1-일-4h-1,3-벤조티아진-4-온 유도체 및 포유동물 감염을 치료하기 위한 이의 용도 | |
| JPH06500117A (ja) | 抗腫瘍活性を増強させる２，４−ジアミノキナゾリン誘導体 | |
| JPH05202045A (ja) | 肝炎の処置に有用な１，３−オキサチオラン | |
| JP2014510746A5 (enExample) | ||
| US20190389803A1 (en) | Antiviral drug for severe fever with thrombocytopenia syndrome | |
| HUP0204347A2 (en) | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them and their use | |
| EP1100786B1 (en) | Antiviral pyrimidinedione derivatives and process for the preparation thereof | |
| WO2009119167A1 (ja) | 抗ｒｎａウイルス作用を有するアニリン誘導体 | |
| US20110136840A1 (en) | Anti-infective agents | |
| CA2954724A1 (en) | Phenyl and tertbutylacetic acid substituted pyridinones having anti-hiv effects | |
| SG184955A1 (en) | 2',2-bisthiazole non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof | |
| US20020128307A1 (en) | Chemokine receptor antagonists | |
| CS227301B2 (en) | Method of preparing n-substituted aziridine-2-carboxylic acid derivatives | |
| RU2395508C1 (ru) | Новые производные бензотиазинона и их применение в качестве антибактериальных средств | |
| WO2024077024A2 (en) | Indazole pyridone compounds and uses thereof | |
| US20050032822A1 (en) | Dithiocarbamate derivatives and their use as antibacterial agents | |
| KR20230161962A (ko) | 나이세리아 고노르호애의 치료 방법 및 재료 | |
| EP2181998A1 (en) | New benzothiazinone derivative and its use as antibacterial agent |